Monte Rosa Therapeutics, Inc. 8-K

What Happened Monte Rosa Therapeutics, Inc. (ticker: GLUE) filed a Form 8-K on May 7, 2026 under Item 2.02 to announce its financial results for the quarter ended March 31, 2026. The company furnished the full press release containing those results as Exhibit 99.1 to the 8-K. The filing is signed by Markus Warmuth, President and Chief Executive Officer.

Key Details

• Filing date: May 7, 2026 (Form 8-K reporting Item 2.02 and Item 9.01).
• Period reported: quarter ended March 31, 2026.
• Press release with the results is furnished as Exhibit 99.1 to the 8-K.
• Report signed by Markus Warmuth, President and CEO.

Why It Matters Quarterly results provide timely information on the company’s revenue, expenses, cash position and operating progress—key inputs for evaluating Monte Rosa’s near-term financial health and prospects. The 8-K itself furnishes the press release rather than restating detailed financials in the filing, so investors should review Exhibit 99.1 (the May 7, 2026 press release) and any subsequent SEC filings for the specific numbers and management commentary.